Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon lambda 1a - Eiger BioPharmaceuticals/ZymoGenetics

Next Previous
X
Search
Drug Profile

Peginterferon lambda 1a - Eiger BioPharmaceuticals/ZymoGenetics

Alternative Names: BMS-914143; Lambda - Eiger BioPharmaceuticals; PEG-IL-29 - ZymoGenetics; PEG-interferon lambda; PEG-interleukin-29 - ZymoGenetics; PEG-rIL-29 - ZymoGenetics; Peginterferon lambda-1a - Eiger BioPharmaceuticals/ZymoGenetics; Pegylated interferon lambda - Eiger BioPharmaceuticals

Latest Information Update: 05 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Bristol-Myers Squibb; Eiger BioPharmaceuticals, Inc.; University Health Network; ZymoGenetics
  • Class Antivirals; Interferons; Interleukins
  • Mechanism of Action Interleukin 29 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III COVID 2019 infections; Hepatitis D
  • No development reported Multiple sclerosis
  • Discontinued Cancer; Hepatitis B; Hepatitis C

Most Recent Events

  • 23 May 2024 Eiger BioPharmaceuticals in collaboration with NIDDK withdraws a phase II trial in Hepatitis D (Combination therapy) in USA (SC) based on the decision of the principal investigator (NCT05953545)
  • 31 Dec 2023 Eiger BioPharmaceuticals has patent protection for peginterferon lambda 1a in USA and Europe
  • 31 Dec 2023 Eiger BioPharmaceuticals has patents pending for peginterferon lambda 1a in multiple countries worldwide

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top